Conditions: Breast Neoplasms
Keywords: Tumors Neratinib HKI-272 Nerlynx
Allocation: NON_RANDOMIZED | Intervention model: SEQUENTIAL
Enrollment: 73
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and tolerability as well as find the maximum tolerated dose (MTD) for HKI-272. In addition, this study will examine the effects of the study drug on your tumor, and how your body uses and eliminates HKI-272.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None arm 7: None arm 8: None

Interventions: intervention 1: neratinib
Intervention descriptions: intervention 1: HKI-272

Protocol document: